Press Releases

Investors Menu

Episurf Medical intensifies sales and marketing efforts through increased participation at European orthopaedic conferences

“We have identified orthopaedic conferences and in particular, specialist knee meetings, as one of the most productive avenues for meeting surgeons, physicians and key opinion leaders. During two recent conferences in Liverpool and Dresden, we met multiple surgeons who are eager to start using Episurf products. At these conferences, we were able to get valuable insights directly from the medical professionals who have  confirmed there is treatment gap for which  the Episealer® patient specific implant…

Episurf Medical receives CE-marking of its third product and accelerates sales efforts

The Episealer® Femoral Twin is a patient-specific implant for the treatment of larger and more elongated cartilage and underlying bone defects in the condyle and trochlea area. The treatment is aimed to help patients suffering from pain and reduced mobility due to cartilage damage to return to an active lifestyle. ‘’Episurf now has three patient specific products on the market which complement each other and thus allow us to meet the need for treating different…

Episurf Medical AB (publ) publishes Interim Report the first 6 months 2015

Second quarter, 1 April – 30 June 2015 Group compared to 2014 » Group net sales amounted to SEK 263,909 (22,157). » Other operating income amounted to SEK 1,110,025 (95,636). » Income after financial items amounted to SEK -11,384,072 (-9.320,493). » Episurf Medical’s quality management system was granted certification according to ISO 13485:12 and Annex II. » Rosemary Cunningham Thomas took over as the Company’s CEO. » The Episealer® condyle Solo implant was included in…

Swedish medtech company Episurf Medical establishes UK subsidiary and sales team

“We have previously announced that a key strategic goal for 2015 is to build a presence in UK. This market, treatment of knee pain and cartilage damage, represents a significant opportunity for Episurf. Only in 2014, the UK carried out 100 000 knee replacement operations in 400 hospitals and approximately 190 000 arthroscopic procedures”, commented Rosemary Cunningham Thomas, CEO of Episurf Medical.  The first surgeries with the Episurf implant in UK were performed in March…

Episurf Medical appoints Rosemary Cunningham Thomas as new CEO

Rosemary Cunningham Thomas has broad experience leading companies through critical growth stages to become industry-leading players with good profitability. She has been the CEO of UK-based ToHealth Ltd., interim CEO of FreeHand 2010 Ltd. and European President & General Manager of Galil Medical. Prior to that, she was Sales and Marketing Director for CR Bard, Inc., listed on the New York Stock Exchange. Rosemary has also held several key positions at Smiths Industries Med Systems…

First surgery performed with Episealer® Knee Trochlea

The first surgery has been performed with Episealer Knee Trochlea, the second commercial product of Episurf Medical. Episealer® Knee Trochlea is intended to treat cartilage defects in the area behind the patella (kneecap). The surgery was carried out by Professor Peter Verdonk from AZ Monica Hospital in Belgium. The patient was a 47 year old male with knee pain despite previous inventions. “It is known that biological treatment solutions are less effective for middle aged…

Patients story 1 year after Episurf operation/procedure

In the video the 31-year old father of two speaks about his everyday life before the procedure, how he suffered from severe discomfort and having difficulty sleeping. “I couldn’t walk 50 meters without feeling pain in my knee. I felt a stinging sensation and suffered from constant pain while sleeping. Several specialists told me that I would never be able to return to my line of work as a carpenter. It was a difficult time…

Episurf Medical secures CE-certification of another product for personalized treatment of knee joint damage: Episealer® Trochlea.

Episurf Medical’s new product, Episealer® Trochlea, is based on the company’s personalized implants. It is intended to treat cartilage defects in the area behind the patella (kneecap). The product now has CE-certification and we will start offering it to selected clinics immediately, via a CPL. The company’s first product, its personalized Episealer® Femoral Condyle, has been in a CPL for the past year. “Over the past year, we’ve affiliated major clinics and key opinion leaders…

Subscribe to our Investor updates